ASCO is the world's leading professional organization representing physicians who care for people with cancer. More than 70 McKesson Specialty Care Solutions | US Oncology affiliated oncology experts have contributed to more than 60 studies being featured at this year's major medical meeting.

"US Oncology Research affiliated investigators are consistently on the cutting edge when it comes to the life-changing therapies of the future," said Nicholas Vogelzang, MD, oncologist at Comprehensive Cancer Centers of Nevada, co-chair of the Genitourinary Committee for US Oncology Research, and the communications chair of the 2011 ASCO Annual Meeting. "When it comes to advancing cancer care, these investigators are contributing in a major way. Take the MEK inhibitor study for example. The investigators understand molecular mechanisms, work with companies which have drugs targeting those mechanisms and use them to successfully treat patients in their practices. This is translational research at its best."

The four studies being presented orally at ASCO by US Oncology Research affiliated physicians are as follows:

"Studies such as these are leading to advances in treating cancer," said John Pippen, MD, FACP, Texas Oncology. "Our US Oncology clinical trials lead to approval of new drugs, better treatment combinations, and better prediction of whether a patient will benefit from a particular cancer treatment."

In addition to these oral presentations, Thomas E. Hutson, DO, PharmD, FACP, Texas Oncology, will be speaking during an education session on the management of unique subsets of patients with renal cell cancer. This session takes place on Sunday, June 5 in Hall D2 from 11:30 AM12:45 PM.

US Oncology Research has a long history of bringing innovative and successful agents to market. To date, US Oncology Research has played a role in the development of 43 FDA approved cancer fighting therapies.

Other presentations that McKesson Specialty Care Solutions | US Oncology affiliated investigators are part of include: